Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 11254653 NLRP3 inflammasome inhibitors

Patent 11254653 was granted and assigned to Novartis on February, 2022 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

Patent

Patent attributes

Patent Applicant

Novartis

Current Assignee

Novartis

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

112546530

Patent Inventor Names

Philipp Janser0

Nichola Smith0

Nikolaus Johannes Stiefl0

Nina Gommermann0

Anette von Matt0

Angela Mackay0

Catherine Fooks Solovay0

Christopher Farady0

...

Date of Patent

February 22, 2022

Patent Application Number

168749050

Date Filed

May 15, 2020

Patent Citations Received

‌

US Patent 11618751 Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives

Patent Primary Examiner

‌

Matthew P Coughlin

Patent abstract

The present invention relates to novel pyridazin-3-yl phenol compounds of Formula (I):

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 11254653 NLRP3 inflammasome inhibitors

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Access by API